(MNTA)—Confirmed on today’s MYL CC that FDA recently sent MYL a list of questions about the Copaxone ANDA and that MYL has not yet replied (although they say they plan to reply soon).
Sounds like MYL is at least a year away from potential FDA approval.
Market Data 
Markets 
AI
